Feng Lin, PhD

Health Economics and Value Assessment Senior Director
Sanofi

Poster(s):

• (385) Real-world treatment history and economic outcomes of CD38 antibody-based regimens in relapsed/refractory multiple myeloma in the United States
  Wednesday, October 29, 2025